PF-04449613

A PDE9A inhibitor

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥325.00

260.00

- +
5mg

￥1562.00

1250.00

- +
10mg

￥2687.00

2150.00

- +
25mg

￥5862.00

4690.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

PF-04449613 is a phosphodiesterase 9A (PDE9A) inhibitor (IC₅₀ = 22 nM).¹ It is selective for PDE9A over PDE1C (IC₅₀ = >1,000 nM), as well as over a variety of other PDEs, inhibiting PDE2-8, -10, and -11 activity by less than 30% in a panel of enzymes, ion channels, and transporters at 1 µM but does inhibit the human dopamine transporter (DAT; K_i = 293 nM). PF-04449613 (0.1-100 mg/kg, s.c.) increases cerebrospinal fluid (CSF) levels of cyclic GMP (cGMP) in rats. Subcutaneous administration of PF-04449613 (10 mg/kg) increases the rate of dendritic spine formation and elimination in mouse primary motor cortex pyramidal neurons in vivo.² It increases the average running speed of mice in an accelerating rotarod task, indicating improved motor learning, at the same dose.

1.Claffey, M.M., Helal, C.J., Verhoest, P.R., et al.Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsJ. Med. Chem.55(21)9055-9068(2012) 2.Lai, B., Li, M., Hu, A., et al.The phosphodiesterase 9 inhibitor PF-04449613 promotes dendritic spine formation and performance improvement after motor learningDev. Neurobiol.78(9)859-872(2018)